Current anti-angiogenic therapy targeting VEGF and its related pathways has not achieved the desired results in osteosarcoma, which has forced scientists to explore new anti-angiogenic strategies (3, 16, 25). This evidence concerns the gene VEGFA and osteosarcoma.